miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Xinjun LiMeng JiaoJing HuMei QiJing ZhangMingfeng ZhaoHui LiuXueting XiongXuesen DongBo HanPublished in: The Prostate (2020)
Our results suggest that miR-30a inhibits AI growth of PCa by targeting MYBL2, FOXD1, and SOX4. They provide novel insights into developing new treatment strategies for CRPC.